Rising regenerative medicine investment drives stem cell market growth

Increased investment and clinical trials in regenerative medicine support demand.

The global stem cell therapy market is projected to grow from about $0.48b in 2026 to $3.65b by 2035, according to MarketsandMarkets™.

Growth is being driven by the rising prevalence of chronic and degenerative diseases, increased investment in regenerative medicine, and expanding clinical trials for stem cell-based treatments.

Advances in induced pluripotent stem cell (iPSC) technology and the growing use of allogeneic stem cell platforms are also supporting market expansion.

Technological improvements in cell sourcing, isolation, ex vivo expansion, automated and closed-system manufacturing, cryopreservation, potency testing, and quality control are making production more scalable and consistent.

The report noted that these developments are helping address challenges in both autologous therapies, which require strict patient-specific tracking, and allogeneic therapies, which depend on standardised, off-the-shelf cell production.

Stricter GMP and CMC regulations, along with requirements for donor eligibility, sterility, traceability, and post-market safety monitoring, are also pushing companies toward more controlled and validated manufacturing systems.